Illumina Cuts Price of Whole-Genome Sequencing for Individuals by More than Half
June 08, 2011 4:47 PM
Illumina, Inc. (NASDAQ: ILMN) today announced a series of measures to increase access to genetic information by individuals and physicians who participate in the company's Individual Genome Sequencing service.
In his remarks at the 3rd annual Consumer Genetics Show in Boston, Illumina President and CEO Jay Flatley announced a significant price reduction for its individual genome sequencing service from $19,500 to $9,500. Additionally, the Company is offering a program to subsidize sequencing for patients with life-threatening disease where whole-genome sequence information may provide their physician with critical tools for diagnosis or treatment.
The price under this program is $7,500 per genome and, for cancer patients, $10,000 for a tumor-normal pair.
